Antengene (6996) investor relations material

Executive summary

• Revenue surged to RMB513.1 million for H1 2026, mainly due to licensing and collaboration deals for ATG-201 and ATG-106, compared to RMB53.2 million in H1 2025.

• Net profit reached RMB216.3 million, reversing a loss of RMB76.4 million year-over-year, driven by upfront payments from UCB and K2 Therapeutics.

• R&D costs increased to RMB122.9 million, reflecting intensified drug development activities.

• Commercial asset XPOVIO® (selinexor) expanded reimbursement in South Korea and maintained approvals in 10 APAC markets.

• Pipeline advanced with new clinical and preclinical programs, including pivotal Phase III for ATG-022 and IND approval for ATG-201.

Financial highlights

• Revenue rose by RMB459.9 million year-over-year, with licensing/collaboration revenue at RMB457.8 million.

• Gross profit increased to RMB480.4 million from RMB42.9 million year-over-year.

• Adjusted profit (excluding share-based payments) was RMB217.2 million, up from a loss of RMB72.9 million.

• Selling and distribution expenses decreased to RMB35.2 million, and administrative expenses fell to RMB35.9 million.

• Other expenses rose sharply to RMB77.3 million, mainly due to foreign exchange losses.

Outlook and guidance

• Focus remains on accelerating development of high-potential clinical assets, especially ATG-022 and ATG-037.

• Continued expansion of XPOVIO® market penetration and reimbursement access in APAC.

• No interim dividend declared for H1 2026.